Cirrhosis is a progressive chronic liver disease resulting in fibrogenesis. Cirrhosis associated various etiologies can cause increased mortality rate worldwide. The liver cirrhotic patients exhibit systemic inflammation, multiple cytokines are produced and involved in progression of disease. Serum levels of IL-6 and ammonia are associated with complications in patients with liver cirrhosis. To evaluate association between IL-6 and ammonia in prognosis and diagnosis of liver cirrhotic patients. A total of 176 participants were included in this study, out of which 88 were liver cirrhotic patients. Recruited patients were showing various etiological factors. Child-Pugh scoring was used to assess severity of liver cirrhosis. IL-6 and ammonia levels were estimated among all participants. Independent t-tests were used to find the differences between the groups and area under the curve (AUC) were conducted to analyze the data. The mean age of cirrhotic patients was 47.1±6.7 years. The patients were categorized under MELD (29.08±1.599) and Child-Pugh score. As per the Child-Pugh scoring around 38 patients were coming under stage C which is the end stage of liver disease. The liver function specific markers such as AST and ALT showed an AUC of 0.965 and 0.986 respectively. The predictive performance of IL-6 (AUROC, 0.972) and Ammonia (AUROC of 0.980) and significant correlation has been observed during the progression of liver cirrhosis. Study related to combination of markers as non-invasive methods indicate the severity of the disease. IL-6 and ammonia may be considered as diagnostic biomarkers to estimate severity of liver cirrhosis. The potential synergistic interaction between IL-6 and ammonia based standardized testing and interpretation guidelines may enhance improved patient care with cirrhosis and hepatic encephalopathy.